Soluble and glyco-lipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate

Bonnet S; Petres S; Holm I; Fontaine T; Rosario S; Roth C; Longacre S

首页> 外文期刊>Vaccine >Soluble and glyco-lipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate

【24h】

Soluble and glyco-lipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate

机译：可溶性和糖脂修饰的杆状病毒恶性疟原虫C端裂殖子表面蛋白1，两种主要的疟疾候选疫苗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Recombinant homologues of the Plasmodium merozoite surface protein 1 C-terminus are leading blood stage malaria vaccine candidates. MSP1 is anchored to the merozoite plasma membrane in vivo by a glycosyl-phosphatidyl-inositol (GPI) moiety, implicated in malaria pathology. Two types of recombinant Plasmodium falciparum MSP1p19 (PfMSP1p19) expressed in baculovirus/insect cells are described here: (1) a soluble, secreted form (PfMSP1p19S) and (2) detergent soluble cellular form(s) (PfMSP1p19+A), released from the infected cell surface by treatment with GPI specific phosphatidyl-inositol phospholipase C (PI-PLC). Soluble and cellular PfMSP1p19 were purified and characterized using SDS-PAGE, mass spectrometry (MS), N-terminal amino acid sequencing, gel filtration and glycan analyses. Quantitative inositol dosage suggested that surface GPI processed entities constituted only 14% of the purified cellular PfMSP1p19+A, with GPI unprocessed forms likely recovered in the endoplasmic reticulum. Nevertheless, this preparation has dramatic immuno-stimulatory activity to be described elsewhere. The interest of these results for both malaria specific and generic vaccine development are discussed.

机译：疟原虫裂殖子表面蛋白1 C-末端的重组同源物是主要的血液阶段疟疾疫苗候选者。 MSP1通过糖基磷脂酰肌醇（GPI）部分在体内锚定于裂殖子质膜，与疟疾病理学有关。此处描述了在杆状病毒/昆虫细胞中表达的两种类型的重组恶性疟原虫MSP1p19（PfMSP1p19）：( 1）可溶性分泌形式（PfMSP1p19S）和（2）去污剂可溶性细胞形式（PfMSP1p19 + A），从通过用GPI特异性磷脂酰肌醇磷脂酶C（PI-PLC）处理感染的细胞表面。使用SDS-PAGE，质谱（MS），N端氨基酸测序，凝胶过滤和聚糖分析对可溶性和细胞性PfMSP1p19进行纯化和表征。定量肌醇剂量表明，表面GPI处理的实体仅占纯化细胞PfMSP1p19 + A的14％，而GPI未经处理的形式很可能在内质网中回收。然而，该制剂具有显着的免疫刺激活性，将在别处描述。讨论了这些结果对疟疾特异性和通用疫苗开发的兴趣。

著录项

来源
《Vaccine》 |2006年第34期|共12页
作者
Bonnet S; Petres S; Holm I; Fontaine T; Rosario S; Roth C; Longacre S;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类卫生标准、卫生检查、医药管理;
关键词

相似文献

外文文献
中文文献
专利

1. Soluble and glyco-lipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate [J] . Bonnet S, Petres S, Holm I, Vaccine . 2006,第33a34期

机译：可溶性和糖脂修饰的杆状病毒恶性疟原虫C端裂殖子表面蛋白1，两种主要的疟疾候选疫苗
2. Crystal Structure of a Fab Complex Formed with PfMSP1-19, the C-terminal Fragment of Merozoite Surface Protein 1 from Plasmodium falciparum: A Malaria Vaccine Candidate. [J] . Pizarro JC, Chitarra V, Verger D, Journal of Molecular Biology . 2003,第5期

机译：用恶性疟原虫裂殖子表面蛋白1的C末端片段PfMSP1-19形成的Fab复合物的晶体结构：疟疾疫苗候选者。
3. Malaria Vaccine-Related Benefits of a Single Protein Comprising Plasmodium falciparum Apical Membrane Antigen 1 Domains I and II Fused to a Modified Form of the 19-Kilodalton C-Terminal Fragment of Merozoite Surface Protein 1 [J] . Bart W. Faber, Edmond J. Remarque, William D. Morgan, Infection and immunity . 2007,第12期

机译：包含恶性疟原虫顶端膜抗原1结构域I和II的单个蛋白质与疟疾疫苗相关的益处融合至修饰形式的裂殖子表面蛋白1的19-Kilodalton C末端片段
4. Immunogenicity of Malaria Vaccine Candidate-Plasmodium falciparum Merozoite Surface Protein 5 (PfMSP5) Expressed in Bacillus subtilis [C] . Chittibabu Gottimukkala, Charles Ma, Hans J. Netter International Conference on Chemical, Biological and Environmental Engineering . 2014

机译：疟疾疫苗候选疟原虫的免疫原性是恶魔植物在枯草芽孢杆菌中表达的疟原虫候选疟原虫疟原虫表面蛋白5（PFMSP5）
5. The impact of the C-terminal conserved region of Plasmodium falciparum's merozoite surface protein-1 and within-host diversity on naturally acquired immunity to malaria. [D] . Branch, OraLee Hipp. 2001

机译：恶性疟原虫裂殖子表面蛋白-1的C端保守区和宿主内部多样性对自然获得的抗疟疾免疫力的影响。
6. Malaria Vaccine-Related Benefits of a Single Protein Comprising Plasmodium falciparum Apical Membrane Antigen 1 Domains I and II Fused to a Modified Form of the 19-Kilodalton C-Terminal Fragment of Merozoite Surface Protein 1 [O] . Bart W. Faber, Edmond J. Remarque, William D. Morgan, 2007

机译：包含恶性疟原虫顶端膜抗原1域I和II的单个蛋白质与疟疾疫苗相关的益处融合到修饰形式的裂殖子表面蛋白1的19-Kilodalton C末端片段
7. Purification and characterization of a malaria vaccine candidate: Plasmodium falciparum merozoite surface protein-1 C-terminal processing fragment (MSP-142) expressed by baculovirus in silkworm larvae. [O] . 2003

机译：疟原虫候选物的纯化和表征：由家蚕幼虫中的杆状病毒表达的恶性疟原虫裂殖子表面蛋白-1C-末端加工片段（msp-142）。

Soluble and glyco-lipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate

摘要

著录项

相似文献

相关主题

期刊订阅